Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

April 12, 2022 updated by: Nanjing First Hospital, Nanjing Medical University

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

Study Overview

Status

Completed

Conditions

Type2 Diabetes

Detailed Description

The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.

Study Type

Observational

Enrollment (Actual)

1713

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with type 2 diabetes who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016 were enrolled in this study.

Description

Inclusion Criteria:

Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

Exclusion Criteria:

Patients use systemic steroidal anti-inflammatory drugs.
Patients are pregnant.
Patients with an acute infection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lipoprotein-associated Phospholipase A2 Time Frame: Day one	the plasma lipoprotein-associated phospholipase A2 level of patients	Day one

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HbA1c Time Frame: Day one	the glycosylated hemoglobin level of patients	Day one
LDL-c Time Frame: Day one	low density lipoprotein cholesterol	Day one
Diabetic Complication Time Frame: Day one	the prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy	Day one
C Peptide Time Frame: Day one	fast and 120min postprandial C peptide	Day one

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nanjing First Hospital, Nanjing Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Hu Y, Li TT, Zhou W, Lu TT, Li FF, Ding B, Liu BL, Xie XJ, Ma JH. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease. Diabetes Res Clin Pract. 2019 Apr;150:194-201. doi: 10.1016/j.diabres.2019.03.026. Epub 2019 Mar 20.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2015

Primary Completion (Actual)

August 31, 2016

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

November 29, 2017

First Submitted That Met QC Criteria